Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,499.60
(
0.38%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
73,500.72
(
0.71%
)
News Focus
News Focus
Post# of 257383
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

acgood

Send PM Follow Ignore
Followers 17
Posts 1093
Boards Moderated 0
Alias Born 05/12/2007

acgood

Re: DewDiligence post# 158196

Tuesday, 03/12/2013 6:41:03 PM

Tuesday, March 12, 2013 6:41:03 PM

Post# of 257383

LOL re SPPI's excuse for the shortfall (generic competition).



Huh? In this case, it is the actual reason. SPPI has bogusly been claiming that their market share gains during the leocovorin shortage were "sticky" and would not reverse when generics became widely available. Today they are admitting reality, not making an excuse.

What they need an excuse for is guiding for 300+ million in 2013 revenue 3 weeks ago but 160-180m today

Any comments here may have previously been disseminated on Twitter @BioDueDiligence or at www.biotechduediligence.com

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today